Table 2 Percentage of low and high infliximab serum trough levels and presence of anti-infliximab antibodies in patients with low and high DAS28 at the first study visit
No infliximab serum trough level | Low* infliximab trough levels | Intermediate infliximab trough levels | High** infliximab trough levels | Anti-infliximab antibodies | Total | |
|---|---|---|---|---|---|---|
DAS28 | % (95%CI) | % (95%CI) | % (95%CI) | % (95%CI) | % (95%CI) | No patients |
<2.6 | 13 (2–23) | 23 (10–35) | 48 (32–63) | 18 (6–29) | 13 (2–23) | 40 |
≤3.2 | 13 (4–20) | 18 (9–28) | 55 (43–67) | 14 (5–22) | 11 (3–19) | 65 |
>3.2 | 29 (19–39) | 18 (10–27) | 32 (22–42) | 21 (12–30) | 29 (19–39) | 82 |